AU2006224313B2 - Method for actvating Natural Killer cells by tumor cell preparation in vitro - Google Patents

Method for actvating Natural Killer cells by tumor cell preparation in vitro Download PDF

Info

Publication number
AU2006224313B2
AU2006224313B2 AU2006224313A AU2006224313A AU2006224313B2 AU 2006224313 B2 AU2006224313 B2 AU 2006224313B2 AU 2006224313 A AU2006224313 A AU 2006224313A AU 2006224313 A AU2006224313 A AU 2006224313A AU 2006224313 B2 AU2006224313 B2 AU 2006224313B2
Authority
AU
Australia
Prior art keywords
cells
cell
tumour
cancer
lysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006224313A
Other languages
English (en)
Other versions
AU2006224313A1 (en
Inventor
Mark W. Lowdell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505508A external-priority patent/GB0505508D0/en
Priority claimed from GB0514288A external-priority patent/GB0514288D0/en
Application filed by UCL Biomedica PLC filed Critical UCL Biomedica PLC
Publication of AU2006224313A1 publication Critical patent/AU2006224313A1/en
Application granted granted Critical
Publication of AU2006224313B2 publication Critical patent/AU2006224313B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Mycology (AREA)
AU2006224313A 2005-03-17 2006-03-16 Method for actvating Natural Killer cells by tumor cell preparation in vitro Ceased AU2006224313B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0505508A GB0505508D0 (en) 2005-03-17 2005-03-17 Method
GB0505508.2 2005-03-17
GB0514288.0 2005-07-12
GB0514288A GB0514288D0 (en) 2005-07-12 2005-07-12 Method
PCT/GB2006/000960 WO2006097743A2 (en) 2005-03-17 2006-03-16 Method for actvating natural killer cells by tumor cell preparation in vitro

Publications (2)

Publication Number Publication Date
AU2006224313A1 AU2006224313A1 (en) 2006-09-21
AU2006224313B2 true AU2006224313B2 (en) 2011-08-11

Family

ID=36992099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006224313A Ceased AU2006224313B2 (en) 2005-03-17 2006-03-16 Method for actvating Natural Killer cells by tumor cell preparation in vitro

Country Status (9)

Country Link
US (3) US8257970B2 (enExample)
EP (2) EP1863905B1 (enExample)
JP (3) JP5663135B2 (enExample)
AU (1) AU2006224313B2 (enExample)
CA (1) CA2601197C (enExample)
DK (1) DK1863905T3 (enExample)
ES (1) ES2566335T3 (enExample)
PL (1) PL1863905T3 (enExample)
WO (1) WO2006097743A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
AU2009259699B2 (en) * 2008-05-29 2014-01-23 Transgene Sa Biomarker for selecting patients and related methods
SG177595A1 (en) * 2009-07-10 2012-03-29 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
WO2013132256A1 (en) 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2016033690A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
US10758567B2 (en) 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
JP6850297B2 (ja) * 2015-12-07 2021-03-31 イミューン ベンチャーズ, リミテッド ライアビリティ カンパニーImmune Ventures, Llc ナチュラルキラー細胞の生体内プライミング
EP3596201A4 (en) * 2017-03-15 2020-12-09 Immune Ventures, LLC IN VIVO PRIMING OF NATURAL KILLER CELLS
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CA3109361A1 (en) * 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
KR20210069639A (ko) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. 단일-사슬 키메라 폴리펩타이드 및 이의 용도
EP3844181B1 (en) 2018-08-30 2025-11-12 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
CN114269903B (zh) * 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
US12398189B2 (en) 2020-02-11 2025-08-26 HCW Biologics, Inc. Methods of activating regulatory T cells
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
IL295077A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods of treating age-related and inflammatory diseases
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20250118299A (ko) * 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263205T3 (es) * 1997-04-30 2006-12-01 Hans Klingemann Estirpes celulares citoliticas naturales y metodos de uso.
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods

Also Published As

Publication number Publication date
EP2399594B1 (en) 2019-08-14
US20140079678A1 (en) 2014-03-20
EP1863905B1 (en) 2016-01-20
US9655925B2 (en) 2017-05-23
EP2399594A1 (en) 2011-12-28
JP2013009686A (ja) 2013-01-17
US20080166326A1 (en) 2008-07-10
EP1863905A2 (en) 2007-12-12
DK1863905T3 (en) 2016-04-04
CA2601197A1 (en) 2006-09-21
JP5663135B2 (ja) 2015-02-04
JP2008536487A (ja) 2008-09-11
AU2006224313A1 (en) 2006-09-21
WO2006097743A2 (en) 2006-09-21
ES2566335T3 (es) 2016-04-12
US8257970B2 (en) 2012-09-04
JP5906168B2 (ja) 2016-04-20
US8637308B2 (en) 2014-01-28
HK1112483A1 (zh) 2008-09-05
PL1863905T3 (pl) 2016-07-29
CA2601197C (en) 2017-06-06
US20120328587A1 (en) 2012-12-27
JP2015012876A (ja) 2015-01-22
WO2006097743A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
US9655925B2 (en) Method for activating natural killer cells by tumor cell preparation in vitro
US11766456B2 (en) Method for culturing natural killer cells using T cells
AU2018346818B2 (en) Expansion and use of expanded NK cell fractions
EP3786287A1 (en) Cd3-negative cell population expressing chemokine receptor and cell adhesion molecule, use thereof, and method for producing same
EP3834849A1 (en) Method for treating tumor using immune effector cell
JP2025072546A (ja) 血液疾患を治療するためのキット
JP2024508906A (ja) 極めて強力なｍ－ｃｅｎｋ細胞及び方法
AU2018311096A1 (en) Treating and inhibiting leukemia with NK-92 cells
HK1112483B (en) Method for activating natural killer cells by tumour cell preparations in vitro
CN117120596A (zh) 高效的m-cenk细胞和方法
HK40005831A (en) Expansion and use of expanded nk cell fractions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired